SignalCorporate
Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growth
Castle Biosciences signals $385M-$395M 2026 revenue outlook with TissueCypher targeting 50%-52% volume growth.
What changed
Castle Biosciences signals $385M-$395M 2026 revenue outlook with TissueCypher targeting 50%-52% volume growth.
Why it matters
Castle Biosciences signals $385M-$395M 2026 revenue outlook with TissueCypher targeting 50%-52% volume growth. — impact context not separately stored; see What changed.